Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma
Recruitment status was: Active, not recruiting
RATIONALE: Immunotherapy uses different ways to stimulate the immune system and stop cancer cells from growing. Immunotherapy biological extracts may be useful as adjuvant therapy in treating patients who have had surgery for breast cancer, colon cancer, or melanoma.
PURPOSE: Phase III trial to study the effectiveness of Corynebacterium granulosum extract as maintenance immunotherapy following surgery in treating patients with breast cancer, colon cancer, or melanoma.
Biological: Corynebacterium granulosum P40
Procedure: adjuvant therapy
|Study Design:||Primary Purpose: Treatment|
|Official Title:||Immunotherapy of Colon Cancer With Autologous Perchloric Soluble Tumors Extracts|
- Recurrence [ Designated as safety issue: No ]
- Response to study parameters [ Designated as safety issue: No ]
- Survival rate [ Designated as safety issue: No ]
|Study Start Date:||April 1971|
- Determine the survival of patients with colon cancer, breast cancer, or melanoma with minimal residual disease after surgical resection treated with maintenance immunotherapy using Corynebacterium granulosum P40.
- Determine leucocyte adherence inhibition, an indication of metastases, over time in patients treated with this regimen.
OUTLINE: This is a multicenter study. Patients are stratified by center and are matched with case-controls by disease type and stage.
Beginning 2 weeks after surgical resection, patients receive Corynebacterium granulosum P40 subcutaneously weekly for 6 weeks, followed by rest for 3 months. Treatment continues for life.
Patients are followed for survival.
PROJECTED ACCRUAL: Not specified
Please refer to this study by its ClinicalTrials.gov identifier: NCT00002455
|Centro Oncologico de Excelencia|
|Gonnet, Buenos Aires, Argentina, 1987 MB|
|Study Chair:||Hugo Omar De Carli, MD||Centro Oncologico de Excelencia|